Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Nimbus Therapeutics is a biotechnology company at the forefront of computational drug discovery. They leverage advanced computational technologies, including physics-based molecular simulations and machine learning, to design and develop breakthrough medicines for a range of serious diseases, focusing on targets that have historically been challenging for traditional drug discovery methods. Their pipeline spans oncology, immunology, and metabolic disorders, with a key focus on harnessing computational power to accelerate the creation of transformative therapies.
The Cambridge headquarters serves as the central hub for Nimbus's research and development, computational drug design, corporate strategy, and administrative operations.
Situated in the heart of Cambridge's biotech cluster, offering modern lab and office spaces designed for collaborative, cutting-edge computational and biological research.
A dynamic, science-first environment emphasizing innovation, collaboration across disciplines (computational sciences, chemistry, biology), and a mission-driven approach to tackling challenging drug targets. The culture encourages rigorous scientific debate and a fast-paced, results-oriented mindset.
Strategic location in Cambridge grants Nimbus direct access to world-class talent from institutions like MIT and Harvard, leading research hospitals, a dense network of biotech peers, and venture capital, fostering innovation and strategic partnerships.
While Nimbus Therapeutics's core research and development operations are based in Cambridge, MA, its scientific collaborations, clinical trial activities, and talent acquisition efforts extend globally. The company engages with international research institutions, contract research organizations (CROs), and clinical sites to advance its pipeline. Its medicines are being developed for diseases that affect patients worldwide, giving its mission a global scope.
130 Brookline Street, Suite 200
Cambridge
MA
USA
Address: N/A
Focus on centralized research & development and corporate functions within the Cambridge biotech ecosystem.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Nimbus Therapeutics' leadership includes:
Nimbus Therapeutics has been backed by several prominent investors over the years, including:
Nimbus Therapeutics significantly strengthened its executive team in the past year with strategic hires for Chief Business Officer and Chief Technology Officer, reflecting its commitment to advancing its pipeline and computational platform. No major C-level departures were publicly announced during this period.
Discover the tools Nimbus Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Nimbus Therapeutics commonly uses the [first].[last]@nimbustx.com email format. Other potential formats might exist but this is a frequently observed pattern for companies of similar structure and industry.
[first].[last]@nimbustx.com
Format
jeb.keiper@nimbustx.com
Example
80%
Success rate
Business Wire • February 27, 2024
Nimbus Therapeutics secured $125 million in a private financing round. The funds are designated to advance its diverse pipeline, including its lead HPK1 inhibitor (NDI-101150) for immuno-oncology, and other programs targeting autoimmune diseases, cancer, and metabolic conditions....more
Nimbus Therapeutics Press Release • February 14, 2024
Nimbus Therapeutics announced the appointment of Abbas Kazimi as its new Chief Business Officer. Mr. Kazimi will lead the company's business development, corporate strategy, and alliance management functions....more
Nimbus Therapeutics Press Release • September 12, 2023
Nimbus Therapeutics appointed Bhaskar Srivastava, Ph.D., as its Chief Technology Officer. Dr. Srivastava will oversee the company's computational platform, data science, and information technology efforts to further enhance its drug discovery capabilities....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Nimbus Therapeutics, are just a search away.